Oncofertility in Canada: Gonadal protection and fertility-sparing strategies

Current Oncology

Volumn 20, Issue 6, 2013, Pages

  Ronn, R ^a   Holzer, H E G ^b  

^a QUEEN S UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Adolescent; Cryopreservation; Fertility preservation; Gonadotoxicity; Oncofertility; Young adult

Indexed keywords

GESTAGEN; GONADORELIN;

ARTICLE; CANADA; CANCER DIAGNOSIS; CANCER MORTALITY; CRYOPRESERVATION; DNA TRANSPOSITION; ENDOMETRIUM CANCER; FERTILITY PRESERVATION; FOLLOW UP; GONAD FUNCTION; HUMAN; MORBIDITY; NEOPLASM; OVARY FUNCTION; PATIENT CARE; PREGNANCY OUTCOME; TREATMENT OUTCOME; TREATMENT RESPONSE; UTERINE CERVIX CANCER;

EID: 84890217143     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Hickey M, Peate M, Saunders CM, Friedlander M. Breast cancer in young women and its impact on reproductive function. Hum Reprod Update 2009;15:323-39.
2. Levine J, Canada A, Stern CJ. Fertility preservation in adolescents and young adults with cancer. J Clin Oncol 2010;28:4831-41.
3. Chen H, Li J, Cui T, Hu L. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011;:CD008018.
4. Blumenfeld Z. How to preserve fertility in young women exposed to chemotherapy? The role of gnrh agonist cotreatment in addition to cryopreservation of embrya, oocytes, or ovaries. Oncologist 2007;12:1044-54.
5. Del Mastro L, Giraudi S, Levaggi A, Pronzato P. Medical approaches to preservation of fertility in female cancer patients. Expert Opin Pharmacother 2011;12:387-96.
6. Blumenfeld Z, von Wolff M. GnRH-analogues and oral contraceptives for fertility preservation in women during chemotherapy. Hum Reprod Update 2008;14:543-52.
7. Beck-Fruchter R, Weiss A, Shalev E. GnRH agonist therapy as ovarian protectants in female patients undergoing chemotherapy: a review of the clinical data. Hum Reprod Update 2008;14:553-61.
8. Clowse ME, Behera MA, Anders CK, et al. Ovarian preservation by gnrh agonists during chemotherapy: a meta-analysis. J Womens Health (Larchmt) 2009;18:311-19.
9. Del Mastro L, Catzeddu T, Boni L, et al. Prevention of chemotherapy-induced menopause by temporary ovarian suppression with goserelin in young, early breast cancer patients. Ann Oncol 2006;17:74-8.
10. Recchia F, Saggio G, Amiconi G, et al. Gonadotropin-releasing hormone analogues added to adjuvant chemotherapy protect ovarian function and improve clinical outcomes in young women with early breast carcinoma. Cancer 2006;106:514-23.
11. Urruticoechea A, Arnedos M, Walsh G, Dowsett M, Smith IE. Ovarian protection with goserelin during adjuvant chemotherapy for pre-menopausal women with early breast cancer (ebc). Breast Cancer Res Treat 2008;110:411-16.
12. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. Breast Cancer Res Treat 2009;117:561-7.
13. Fox KR. Scialla J. Moore H. Preventing chemotherapy related amenorrhea using leuprolide during adjuvant chemotherapy for early-stage breast cancer [abstract]. J Clin Oncol 2003; 22:.
14. Munster PN, Moore AP, Ismail-Khan R, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol 2012;30:533-8.
15. Gerber B, von Minckwitz G, Stehle H, et al. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the gbg 37 zoro study. J Clin Oncol 2011;29:2334-41.
16. Badawy A, Elnashar A, El-Ashry M, Shahat M. Gonadotropinreleasing hormone agonists for prevention of chemotherapyinduced ovarian damage: prospective randomized study. Fertil Steril 2009;91:694-7.
17. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA 2011;306:269-76.
18. Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropinreleasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011;95:906-14. e1-4.
19. Ben-Aharon I, Gafter-Gvili A, Leibovici L, Stemmer SM. Pharmacological interventions for fertility preservation during chemotherapy: a systematic review and meta-analysis. Breast Cancer Res Treat 2010;122:803-11.
20. Meirow D, Rabinovici J, Katz D, Or R, Shufaro Y, Ben-Yehuda D. Prevention of severe menorrhagia in oncology patients with treatment-induced thrombocytopenia by luteinizing hormone-releasing hormone agonist and depo-medroxyprogesterone acetate. Cancer 2006;107:1634-41.
21. Masala A, Faedda R, Alagna S, et al. Use of testosterone to prevent cyclophosphamide-induced azoospermia. Ann Intern Med 1997;126:292-5.
22. Meistrich ML, Shetty G. Hormonal suppression for fertility preservation in males and females. Reproduction 2008;136:691-701.
23. Lee SJ, Schover LR, Partridge AH, et al. on behalf of the American Society of Clinical Oncology. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-31.
24. Casper RF, Jurisicova A. Protecting the female germ line from cancer therapy. Nat Med 2000;6:1100-1.
25. Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109-14.
26. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997;3:1228-32.
27. Tilly JL. Emerging technologies to control oocyte apoptosis are finally treading on fertile ground. ScientificWorldJournal 2001;1:181-3.
28. Dorais J, Dodson M, Calvert J, et al. Fertility-sparing management of endometrial adenocarcinoma. Obstet Gynecol Surv 2011;66:443-51.
29. Eskander RN, Randall LM, Berman ML, Tewari KS, Disaia PJ, Bristow RE. Fertility preserving options in patients with gynecologic malignancies. Am J Obstet Gynecol 2011;205:103-10.
30. Kalogiannidis I, Agorastos T. Conservative management of young patients with endometrial highly-differentiated adenocarcinoma. J Obstet Gynaecol 2011;31:13-17.
31. Ramirez PT, Frumovitz M, Bodurka DC, Sun CC, Levenback C. Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. Gynecol Oncol 2004;95:133-8.
32. Seli E, Tangir J. Fertility preservation options for female patients with malignancies. Curr Opin Obstet Gynecol 2005;17:299-308.
33. Koskas M, Yazbeck C, Walker F, et al. Fertility sparing management of endometrial adenocarcinoma and atypical hyperplasia: a literature review [French]. Bull Cancer 2012;99:51-60.
34. Gotlieb WH, Beiner ME, Shalmon B, et al. Outcome of fertility-sparing treatment with progestins in young patients with endometrial cancer. Obstet Gynecol 2003;102:718-25.
35. Shah MM, Wright JD. Management of endometrial cancer in young women. Clin Obstet Gynecol 2011;54:219-25.
36. Magelssen H, Brydøy M, Fosså SD. The effects of cancer and cancer treatments on male reproductive function. Nat Clin Pract Urol 2006;3:312-22.
37. Bauer K, Skoetz N, Monsef I, Engert A, Brillant C. Comparison of chemotherapy including escalated beacopp versus chemotherapy including abvd for patients with early unfavourable or advanced stage Hodgkin lymphoma. Cochrane Database Syst Rev 2011;:CD007941.
38. Behringer K, Breuer K, Reineke T, et al. Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group. J Clin Oncol 2005;23:7555-64.
39. Viviani S, Santoro A, Ragni G, Bonfante V, Bestetti O, Bonadonna G. Gonadal toxicity after combination chemotherapy for Hodgkin's disease. Comparative results of mopp vs abvd. Eur J Cancer Clin Oncol 1985;21:601-5.
40. O'Neill MT, Ni Dhonnchu T, Brannigan AE. Topic update: effects of colorectal cancer treatments on female fertility and potential methods for fertility preservation. Dis Colon Rectum 2011;54:363-9.
41. Jeruss JS, Woodruff TK. Preservation of fertility in patients with cancer. N Engl J Med 2009;360:902-11.
42. Ganz PA, Land SR, Geyer CE Jr, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the nsabp B-30 trial. J Clin Oncol 2011;29:1110-16.
43. Han SS, Kim YH, Lee SH, et al. Underuse of ovarian transposition in reproductive-aged cancer patients treated by primary or adjuvant pelvic irradiation. J Obstet Gynaecol Res 2011;37:825-9.
44. Bisharah M, Tulandi T. Laparoscopic preservation of ovarian function: an underused procedure. Am J Obstet Gynecol 2003;188:367-70.
45. Wo JY, Viswanathan AN. Impact of radiotherapy on fertility, pregnancy, and neonatal outcomes in female cancer patients. Int J Radiat Oncol Biol Phys 2009;73:1304-12.
46. Morice P, Juncker L, Rey A, El-Hassan J, Haie-Meder C, Castaigne D. Ovarian transposition for patients with cervical carcinoma treated by radiosurgical combination. Fertil Steril 2000;74:743-8.
47. Anderson B, LaPolla J, Turner D, Chapman G, Buller R. Ovarian transposition in cervical cancer. Gynecol Oncol 1993;49:206-14.
48. Nguyen L, Brewer CA, DiSaia PJ. Ovarian metastasis of stage ib1 squamous cell cancer of the cervix after radical parametrectomy and oophoropexy. Gynecol Oncol 1998;68:198-200.
49. Al-Badawi IA, Al-Aker M, AlSubhi J, et al. Laparoscopic ovarian transposition before pelvic irradiation: a Saudi tertiary center experience. Int J Gynecol Cancer 2010;20:1082-6.
50. Picone O, Aucouturier JS, Louboutin A, Coscas Y, Camus E. Abdominal wall metastasis of a cervical adenocarcinoma at the laparoscopic trocar insertion site after ovarian transposition: case report and review of the literature. Gynecol Oncol 2003;90:446-9.
51. Marhhom E, Cohen I. Fertility preservation options for women with malignancies. Obstet Gynecol Surv 2007;62:58-72.
52. Morris SN, Ryley D. Fertility preservation: nonsurgical and surgical options. Semin Reprod Med 2011;29:147-54.
53. Williams RS, Littell RD, Mendenhall NP. Laparoscopic oophoropexy and ovarian function in the treatment of Hodgkin disease. Cancer 1999;86:2138-42.
54. Mazonakis M, Damilakis J, Varveris H, Gourtsoyiannis N. Radiation dose to laterally transposed ovaries during external beam radiotherapy for cervical cancer. Acta Oncol 2006;45:702-7.
55. Huang KG, Lee CL, Tsai CS, Han CM, Hwang LL. A new approach for laparoscopic ovarian transposition before pelvic irradiation. Gynecol Oncol 2007;105:234-7.
56. Clough KB, Goffinet F, Labib A, et al. Laparoscopic unilateral ovarian transposition prior to irradiation: prospective study of 20 cases. Cancer 1996;77:2638-45.
57. Rasool N, Rose PG. Fertility-preserving surgical procedures for patients with gynecologic malignancies. Clin Obstet Gynecol 2010;53:804-14.
58. Pahisa J, Martínez-Román S, Martínez-Zamora MA, et al. Laparoscopic ovarian transposition in patients with early cervical cancer. Int J Gynecol Cancer 2008;18:584-9.
59. Ishiguro H, Yasuda Y, Tomita Y, et al. Gonadal shielding to irradiation is effective in protecting testicular growth and function in long-term survivors of bone marrow transplantation during childhood or adolescence. Bone Marrow Transplant 2007;39:483-90.
60. Sanghvi PR, Kaurin DG, McDonald TL, Holland JM. Testicular shielding in low-dose total body irradiation. Bone Marrow Transplant 2007;39:247-8.
61. Mazonakis M, Damilakis J, Varveris H, Gourtsouiannis N. Radiation dose to testes and risk of infertility from radiotherapy for rectal cancer. Oncol Rep 2006;15:729-33.
62. Rob L, Skapa P, Robova H. Fertility-sparing surgery in patients with cervical cancer. Lancet Oncol 2011;12:192-200.
63. Xu L, Sun F-Q, Wang Z-H. Radical trachelectomy versus radical hysterectomy for the treatment of early cervical cancer: a systematic review. Acta Obstet Gynecol Scand 2011;90:1200-9.
64. Ottosen C. Trachelectomy for cancer of the cervix: Dargent's operation. Vaginal hysterectomy for early cancer of the cervix stage ia1 and cin iii. Best Pract Res Clin Obstet Gynaecol 2011;25:217-25.
65. Morice P, Denschlag D, Rodolakis A, et al. on behalf of the Fertility Task Force of the European Society of Gynecologic Oncology. Recommendations of the Fertility Task Force of the European Society of Gynecologic Oncology about the conservative management of ovarian malignant tumors. Int J Gynecol Cancer 2011;21:951-63.
66. Nam JH. Borderline ovarian tumors and fertility. Curr Opin Obstet Gynecol 2010;22:227-34.
67. Kajiyama H, Shibata K, Mizuno M, et al. Long-term survival of young women receiving fertility-sparing surgery for ovarian cancer in comparison with those undergoing radical surgery. Br J Cancer 2011;105:1288-94.
68. Wright JD, Shah M, Mathew L, et al. Fertility preservation in young women with epithelial ovarian cancer. Cancer 2009;115:4118-26.
69. Gershenson DM. Fertility-sparing surgery for malignancies in women. J Natl Cancer Inst Monogr 2005;(34):43-7.